Abstract: A pharmaceutical aerosol formulation, suitable for administration by oral or nasal inhalation, containing a suspension of particulate budesonide, hydrofluoroalkane propellant and, optionally, additional hydrofluoroalkane propellants, surfactant selected from oleic acid, sorbitan oleates and lecithin, and adjuvant have a Kauri-butanol value of at least 10.

Abstract: An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.

Abstract: Sticky dental compositions which include a sticky, glue-like matrix material for treating a variety of tooth or gum ailments and methods for using such compositions. For maximum comfort, an improved dental tray that is thin-walled, flexible and lightweight is used to hold the sticky dental composition adjacent the desired tooth surfaces. The sticky dental compositions include a sticky matrix material into which is dispersed an appropriate dental agent, such as a bleaching agent, a desensitizing agent, and an anticariogenic agent, an antimicrobial agent. The matrix material preferably includes carboxypolymethylene that has been partially neutralized with a base to reduce etching of the enamel. The carboxypolymethylene adds a unique stickiness to the dental composition which helps to adhere and retain the soft tray material against the person's teeth.

Abstract: Microclustered water is produced from a starting water. First, the starting water is boiled to produce steam. Next, the steam is passed across a magnetic field, and the steam is condensed at a temperature greater than 0.degree. C. in the presence of light in the far infra-red to ultraviolet spectrum range to produce condensed steam. At least one metasilicate salt stabilizer and a dietary supplement template are added to the condensed steam. The concentration of dietary supplement template is 1% or less. The condensed steam is exposed to a pressure greater than 1 atmosphere; and then depressurized to produce the microclustered water. The microclustered water produces an .sup.17 O NMR resonance signal less than 115 Hz, has a conductivity of at least 3.7 .mu.s/cm, and has a surface tension of less than 61 dynes/cm.

Abstract: A composition and method useful for treating commonly occurring inflammatory disease of the nose, ears and sinuses are described. Interleukin-1 (IL-1), a naturally occuring and generally non-toxic composition, is one of the key mediators of the biomolecular inflammatory reaction. IL-1 antagonists have been found in the human body. The IL-1 antagonists are thought to function as natural modulators of the inflammatory response. The present invention employs IL-1 receptor antagonist to block the runaway inflammatory cascade associated with inflammatory disease of the paranasal sinuses and middle ear. The composition and method prevents the long term complications of this disease and reduces the need for costly surgical intervention which is currently performed in more advanced cases.

Abstract: Compounds of Formula I: ##STR1## wherein: X.sub.1, and X.sub.2 are each independently either O.sup.- or S.sup.- ;X.sub.3 and X.sub.4 are each independently either --H or --OH, with the proviso that X.sub.3 and X.sub.4 are not simultaneously --H;R.sub.1 is selected from the group consisting of O, imido, methylene and dihalomethylene;R.sub.2 is selected from the group consisting of H, halo, alkyl, substituted alkyl, alkoxyl, nitro and azido;R.sub.3 is selected from the group consisting of H, alkyl, acyl, aryl, and arylalkyl; andR.sub.4 is selected from the group consisting of --OR', --SR', --NR', and --NR'R", wherein R' and R" are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, alkoxyl, and aryloxyl, with the proviso that R' is absent when R.sub.

Abstract: Described is the use of vitamin E in topically applied compositions for the purpose of enhancing the penetration of therapeutically effective (cosmetically or pharmaceutically-active) drug or cosmetic ingredients. The topical compositions containing the penetration-enhancing concentration of vitamin E may be provided in a variety of forms including semi-solid (gel, paste, cream, lotion, ointment, etc.), liquid, suspension, film or laminate.

Abstract: The present invention relates to compositions containing Group C streptococcal phage associated lysin enzyme for the prophylactic and therapeutic treatment of Streptococcal infections, including the infection commonly known as strep throat. Methods for therapeutically and prophylactically treating such infections also are described.

Abstract: A stable solution cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonoas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: The present invention relates to a pharmaceutical aerosol formulation which comprises particulate anhydrous beclomethasone dipropionate together with 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant, which formulation is free of surfactant. The formulation may also contain salbutamol and includes a canister suitable for delivery and a method of treating respiratory disorders administering the formulation by inhilation.

Abstract: The permeation of a therapeutic agent through the epithelium by topical administration is enhanced by the further topical administration of a stearylamine, transvaccenic acid or a combination of a stearylamine and transvaccenic acid.

Abstract: This invention relates to an aerosol hair spray formulation containing 0.5 to 15 weight percent of a water-dispersible or water-dissipatible, linear sulfopolyester having a Tg of 40.degree. C. to 50.degree. C. and an inherent viscosity of 0.24 to 0.60 dl/g which contains repeat units from 20 to 26 mole percent dimethyl-5-sodiosulfoisophthalate and 74 to 80 mole percent isophthalic acid, based on 100 mole percent dicarboxylic acid; 10 to 30 mole percent 1,4-cyclohexanedimethanol and 70 to 90 percent diethylene glycol, based on 100 mole percent diol; and up to 60 weight percent of an alcohol. The aerosol hair spray formulations are clear, have improved dry time and curl retention, and exhibit less than 20 NTU's, which is a measure of turbidity, even at high concentrations of alcohol.

Abstract: A hair spray composition comprising:(a) about 0.25% to about 6% by weight of a carboxylated polyurethane resin;(b) 0% to about 80% by weight of an alcohol; and(c) about 15% to about 95% by weight water,wherein the carboxylated polyurethane resin has a weight average molecular weight of about 15,000 to about 150,000, and is a reaction product of a mixture comprising:(i) about 10% to about 90% by weight of the mixture of a polyoxyalkylene diol having a number average molecular weight of about 400 to about 20,000;(ii) about 0.01% to about 20% by weight of the mixture of an alkylene glycol;(iii) about 3% to about 80% by weight of the mixture of an organic diisocyanate;(iv) about 0.1% to about 30% by weight of the mixture of a 2,2-di (hydroxymethyl)-alkanoic acid; and(v) about 0.001% to about 0.95% by weight of the mixture of water, wherein a ratio of isocyanate groups to hydroxyl groups is about 0.4 to about 1.1.

Abstract: Provided is a solution aerosol formulation adapted for use in a pressurized aerosol container. The aerosol formulation is formulated from a composition containing Budesonide, Formoterol at least one fluoroalkane propellant, and a cosolvent present in an amount that dissolves or solubilizes the Budesonide and Formoterol in the mixture of cosolvent and propellant.

Abstract: Applications of low-frequency (20 KHz) ultrasound enhances transdermal transport of high-molecular weight proteins. This method includes a simultaneous application of ultrasound and protein on the skin surface in order to deliver therapeutic doses of proteins across the skin. Examples demonstrate in vitro and in vivo administration of insulin (molecular weight 6,000 D), and in vitro administration of gamma interferon (molecular weight 17,000 D), and erythropoeitin (molecular weight 48,000 D).

Abstract: The present invention relates to an oral delivery system containing a group c streptococcal phage associated lysin enzyme for the prophylactic and therapeutic treatment of Streptococcal A throat infections, commonly known as strep throat.

Abstract: The invention relates to oral presentation forms for pantoprazole, which consist of a core, an intermediate layer and an outer layer which is resistant to gastric juice.

Abstract: Suspension formulations suitable for nebulization, for administration by inhalation, comprising fluticasone propionate with a particle size less than 12 microns, one or more surfactants, one or more buffer agents and water. Also described are a method of preparing such a formulation, a container comprising the formulation, and a method of treating asthma using the formulation.

Abstract: Dry powders of .alpha.1-antitrypsin are administered pulmonarily to patients to treat, for example, certain types of emphysema. The dry powder compositions may comprise aggregates of fine particles, which aggregates are friable and break-up upon dispersion in a flowing gas stream. Typically, the dispersed powders are captured in a chamber and subsequently inhaled by a patient for pulmonary treatment of emphysema and other conditions.

Abstract: Normal olfactory function restoration through topical application of an effective amount of fluticasone propionate to the olfactory epithelium. A patient should be started on 1 mg per day dosage and the dosage gradually inreased until the patient regains the sense of smell.